bullish
CanSino Biologics (康希诺) IPO: Valuation Attractive, Lilly Asia Doubling Up (Part 4)
824 Views18 Mar 2019 17:41
CanSino Biologics started its book building today to raise up to USD 160 million to list in Hong Kong. In our previous insights (links provided...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities22 Jul 2020
- CanSino Biologics Placement: Liquidity Permits a Trade but Beware of COVID-19 Hype06 Apr 2020
- CanSino Biologics (康希诺) IPO Trading Update - Time to Cash Out28 Mar 2019
- CanSino Biologics (康希诺) IPO: Valuation Update (Part 3)13 Mar 2019
- CanSino Biologics (康希诺) IPO: Thoughts on Valuation (Part 2)26 Nov 2018
x